Thermo Fisher Scientific expands Applied Biosystems portfolio with the latest generation of innovative, mid-throughput genetic analyzers
Capillary electrophoresis (CE), which enables Sanger sequencing and fragment analysis,is an important tool for improving clinical research and advancing scientific discovery. To further enable customers’ cutting-edge research in areas such as gene editing and infectious disease, Thermo Fisher Scientific introduced the new Applied Biosystems SeqStudio Flex Series Genetic Analyzer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220208005374/en/
The Applied Biosystems SeqStudio Flex Series Genetic Analyzer delivers high-quality Sanger sequencing and fragment analysis data while providing design and technological advancements for enhanced flexibility, usability and connectivity. (Photo: Business Wire)
“Labs around the world rely on Applied Biosystems’ CE-based instruments for gold-standard Sanger sequencing and fragment analysis data,” said Kay Eron, vice president and general manager of capillary electrophoresis, Thermo Fisher Scientific. “As Thermo Fisher celebrates the fortieth anniversary of the Applied Biosystems brand, we will continue to invest in CE technology as a core platform in our sequencing portfolio. We designed the SeqStudio Flex Series Genetic Analyzers with our customers in mind, offering a simplified, more efficient workflow, multiple applications and an exceptional level of accuracy to advance their research.”
Building on proven Applied Biosystems technology, the new mid-throughput genetic analyzer introduces design and technological advancements for enhanced flexibility, usability and connectivity. The instrument has increased plate capacity and may be loaded at any time without cancelling or waiting for a run to complete, improving sample throughput, walk-away capacity and scheduling flexibility.
The system’s advanced Wi-Fi connectivity enables users to remotely set up and monitor runs, as well as to facilitate streamlined data transfer, analysis and scientific collaboration. The SeqStudio Flex Series Genetic Analyzer is also the first CE-based instrument with remote servicing capabilities for faster issue resolution.
“The SeqStudio Flex analyzer is the most intuitive and flexible sequencer we have ever used,” said Peter Böhm, MSc, chief biomedical laboratory scientist for the department of clinical genetics at Righospitalet, a large, specialized hospital in Denmark. “Our work researching genetic diseases relies on fast turn-around times, high data quality and easy connection to equipment specialists during troubleshooting. The SeqStudio Flex package has it all.”
To learn more about the Applied Biosystems SeqStudio Flex Series Genetic Analyzers, visit thermofisher.com/seqstudioflex.
*For research use only. Not for us in diagnostic procedures.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220208005374/en/